The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia

Fruchart, Jean-Charles; Sacks, Frank; Hermans, Michel P.; Assmann, Gerd; Brown, W. Virgil; Ceska, Richard; Chapman, M. John; Dodson, Paul M.; Fioretto, Paola; Ginsberg, Henry N.; Kadowaki, Takashi; Lablanche, Jean-Marc; Marx, Nikolaus; Plutzky, Jorge; Reiner, Željko; Rosenson, Robert S.; Staels, Bart; Stock, Jane K.; Sy, Rody; Wanner, Christoph; Zambon, Alberto; Zimmet, Paul; Residual Risk Reduction Initiative (R3i),

doi:10.1016/j.amjcard.2008.10.002

« PreviousAmerican Journal of Cardiology
Volume 102, Issue 10, Supplement , Pages 1K-34K, 17 November 2008

The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia

Jean-Charles Fruchart, PhD (Co-Chair)
- INSERM UR 545, Institut Pasteur de Lille, Université Lille 2, Lille, France
- Address for reprints: Jean-Charles Fruchart, PhD, Laboratoire J & K, Inserm UR 545, Faculté de Médecine de Lille, Pôle Recherche, Boulevard du Professeur Leclerc, 59045 Lille Cedex, France
Frank Sacks, MD (Co-Chair)
- Nutrition Department, Harvard School of Public Health, Department of Medicine, Harvard Medical School, and Cardiovascular Division and Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts, USA
Michel P. Hermans, MD, PhD (General Secretary)
- Cliniques Universitaires St-Luc, Service d'Endocrinologie et Nutrition, Brussels, Belgium
Gerd Assmann, MD
- Assmann-Stiftung für Prävention, Münster, Germany
W. Virgil Brown, MD
- Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, Georgia, USA
Richard Ceska, MD, PhD
- Center of Preventive Cardiology, University General Hospital, Prague, Czech Republic
M. John Chapman, PhD, DSc
- Dyslipidemia and Atherosclerosis Research Unit, INSERM U.551, Hôpital de la Pitié, Paris, France
Paul M. Dodson, MD
- Medical Ophthalmology, and Diabetes, Heart of England Foundation Trust, Birmingham, UK
Paola Fioretto, MD
- Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
Henry N. Ginsberg, MD
- Department of Medicine and Irving Institute for Clinical and Translational Research, Columbia University, New York, New York, USA
Takashi Kadowaki, MD
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Jean-Marc Lablanche, MD
- Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, Lille, France
Nikolaus Marx, MD
- Department of Internal Medicine II, University of Ulm, Ulm, Germany
Jorge Plutzky, MD
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
Željko Reiner, MD, PhD
- University Hospital Center Zagreb, Zagreb, Croatia
Robert S. Rosenson, MD
- Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA
Bart Staels, PhD
- INSERM UR 545, Institut Pasteur de Lille, Université Lille 2, Lille, France
Jane K. Stock, PhD
- London, UK
Rody Sy, MD
- Lipid Research Unit, Department of Medicine, University of the Philippines-Philippine General Hospital, Manila, Philippines
Christoph Wanner, MD
- Department of Medicine, Division of Nephrology, University Hospital Würzburg, Würzburg, Germany
Alberto Zambon, MD, PhD
- Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
Paul Zimmet, MD, PhD
- International Diabetes Institute, Caulfield, Victoria, Australia
Residual Risk Reduction Initiative (R³i)
- The Residual Risk Reduction Initiative (R³i) is an independent body of basic and clinical scientists, cardiologists, endocrinologists and diabetologists that has been formed to address this issue. It is registered in Switzerland under its legal jurisdiction. This will ensure that the scientists will set the direction and have control of the activities of the R³i. The current funders are Solvay Pharmaceuticals.